International Journal of Cardiology: Heart & Vasculature, 2018 Background: Tolvaptan is a vasopressin type 2 receptor antagonist used in heart failure (HF) with refractory diuretic resistance. However, since tolvaptan is also ineffective in some HF patients with reduced ejection fraction (HFrEF), the identification ...
Shinichi Nonin +9 more
doaj +2 more sources
Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD) [PDF]
Therapeutic Advances in Endocrinology and Metabolism, 2023 The syndrome of inappropriate antidiuresis (SIAD), the commonest cause of hyponatraemia, is associated with significant morbidity and mortality. Tolvaptan, an oral vasopressin V2-receptor antagonist, leads through aquaresis to an increase in serum sodium
Ploutarchos Tzoulis +4 more
doaj +4 more sources
Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia [PDF]
BMC Gastroenterology, 2018 Background Although tolvaptan treatment improves hyponatremia, only few studies have investigated whether tolvaptan actually benefits the survival of cirrhotic patients.
Shuzhen Wang +8 more
doaj +2 more sources
Utility and Safety of Tolvaptan in Cirrhotic Patients with Hyponatremia: a Prospective Cohort Study
Annals of Hepatology, 2017 Introduction and aim: Hyponatremia is common in patients with decompensated cirrhosis and is associated with increased mortality. Tolvaptan, a vasopressor V2 receptor antagonist, can increase free water excretion, but its efficacy and safety in cirrhotic
Ji-Dong Jia +16 more
doaj +2 more sources
ESC Heart FailureAims Renal dysfunction in patients with chronic heart failure predicts a poor prognosis. Tolvaptan has a diuretic effect in patients with chronic kidney disease and heart failure without adverse effects on renal function.
Nobukiyo Tanaka +14 more
doaj +2 more sources
Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre-Specified Secondary Analysis of the TVFR Trial. [PDF]
Clin Endocrinol (Oxf)ABSTRACT Objective Hyponatraemia is a common electrolyte disorder often driven by excess arginine vasopressin (AVP). Copeptin is a stable surrogate marker co‐secreted with AVP. It is unclear whether treatment of hyponatraemia with tolvaptan, an AVP‐V2 receptor antagonist, impacts copeptin.
Warren AM +4 more
europepmc +2 more sources
Intravenous Tolvaptan Sodium Phosphate Can Fail to Improve Fluid Overload Due to Heart Failure in Patients With Chronic Kidney Disease: A Case Report. [PDF]
Pharmacol Res PerspectABSTRACT Tolvaptan is widely used as an adjunct oral diuretic to loop and thiazide diuretics for the management of fluid overload in patients with congestive heart failure. Recently, tolvaptan sodium phosphate (TSP), a water‐soluble prodrug of tolvaptan, was developed for intravenous administration and has demonstrated efficacy and safety in clinical ...
Uno T +10 more
europepmc +2 more sources
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. [PDF]
, 2017 BACKGROUND: In a previous trial involving patients with early autosomal dominant polycystic kidney disease (ADPKD; estimated creatinine clearance, ≥60 ml per minute), the vasopressin V2-receptor antagonist tolvaptan slowed the growth in total kidney ...
Torres, Vicente. +7 more
core +10 more sources
Tolvaptan in ADPKD Patients With Very Low Kidney Function [PDF]
, 2021 Introduction: Tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) in TEMPO 3:4 and REPRISE trials.
Lee, Jennifer +8 more
core +2 more sources
Long-term effects of tolvaptan in patients requiring recurrent hospitalization for heart failure [PDF]
, 2015 2015-08Although reports suggest that tolvaptan does not reduce survival or subsequent hospitalization rates in heart failure patients, its continuous use has shown good outcomes in some patients who cannot be effectively managed with high doses of loop ...
Ishii, Hideki +9 more
core +1 more source